Nexalis Therapeutics Limited has released a press release.
$38.5m Funding to Fully Fund Clinical Development Plans
Filed with ASX ·
6ix hasn’t read this filing yet.
Nexalis Therapeutics Limited on 6ix
Earlier from Nexalis Therapeutics
- Issue of Shares to CEO in Lieu of Accrued Salary
- Jun24 Quarterly Activities Report
- Jun24 Appendix 4C Cash Flow Report
- Mar24 Appendix 4C Cash Flow Report
- Mar24 Quarterly Activities Report
Later from Nexalis Therapeutics
- Sep24 Quarterly Activities Report
- Sep24 Appendix 4C Cash Flow Report
- Ethics Approval for Phase 2 Clinical Trial of IRX-211
- Issue of Securities Following General Meeting Approval
- Shareholder Update
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics